Imatinib vs Dasatinib: Which is Better

SEO Meta & Title

Page Title

Meta Description

Compare Imatinib vs Dasatinib for CML treatment. Learn safety, efficacy, pricing, India generic options, and expert sourcing guidance for 2026.

Hero Section (Above-the-Fold)

H1 Title

Imatinib vs Dasatinib: Which is Better for First-Line CML Therapy?

Hero Subtitle

Choosing between Imatinib and Dasatinib depends on clinical goals, patient tolerance, and long-term cost planning. This guide compares efficacy, safety, India generic access, and procurement advantages for both therapies in 2026.

CTA Buttons

Request Latest Quote

Talk to Oncology Supply Expert

Suggested Hero Image

Imatinib vs Dasatinib which is better for first-line CML treatment comparison

Drug Overview

When evaluating Imatinib vs Dasatinib: which is better, the answer depends on disease stage, mutation profile, patient tolerance, and treatment affordability. Both drugs are tyrosine kinase inhibitors (TKIs) used primarily in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Imatinib was the first revolutionary targeted therapy for CML and was originally launched by Novartis under the brand name Gleevec. Approved by the U.S. FDA in 2001, it transformed leukemia care by specifically inhibiting the BCR-ABL tyrosine kinase responsible for cancer progression. It also targets KIT and PDGF receptors, making it useful in GIST and other malignancies.

Dasatinib, marketed originally by Bristol Myers Squibb as Sprycel, is a second-generation TKI approved in 2006. It is more potent against BCR-ABL and can overcome some resistance mutations that limit Imatinib effectiveness. Dasatinib is often preferred for patients needing faster molecular response or those intolerant to first-generation therapy.

Clinical studies such as the DASISION trial demonstrated faster and deeper molecular responses with Dasatinib compared to Imatinib in newly diagnosed CML patients. However, long-term survival outcomes remain strong for both treatments, and Imatinib remains widely used because of excellent safety familiarity and significantly lower cost.

Regarding safety, Imatinib commonly causes nausea, edema, muscle cramps, rash, and fatigue. Dasatinib may cause pleural effusion, thrombocytopenia, pulmonary complications, and stronger immunosuppression. Patient monitoring is critical with both therapies.

From a procurement perspective, India generic versions of both medicines offer substantial savings. Leading manufacturers such as Natco, Cipla, Hetero, Dr. Reddy’s, and Sun Pharma provide WHO-GMP and USFDA-compliant formulations, supporting both patients and institutional buyers worldwide.

Original Brand vs India Generic Comparison

Parameter	Original Brand	India Generic
Imatinib Brand	Gleevec (Novartis)	Veenat / Imatib / Generic Imatinib
Dasatinib Brand	Sprycel (BMS)	Dasanat / Dasatinib Generic
Strengths	100mg / 400mg	Equivalent strengths available
Cost	High	60–85% lower
Certification	USFDA / EMA	WHO-GMP / USFDA / EU GMP
Global Access	Limited by pricing	Broad international supply support

India Generic Imatinb 100 mg (usd35-40/box)

Why Choose India Generic

India is the leading global source for affordable oncology generics, especially for long-term leukemia therapies like Imatinib and Dasatinib. For hospitals, distributors, NGOs, and individual patients, generic sourcing improves treatment continuity and budget sustainability.

Major Cost Reduction: Generic versions reduce therapy cost by 60–85% compared to original brands.
WHO-GMP Certified Production: Strict compliance ensures reliable product quality and safety.
USFDA and EU GMP Facilities: Multiple manufacturers meet export standards for regulated markets.
High Manufacturing Capacity: Stable supply supports institutional procurement and global tenders.
Reliable API Supply Chain: Strong domestic API production improves continuity and reduces shortages.
9S Network Assurance: Verified sourcing, documentation support, and export coordination reduce procurement risks.
Flexible MOQ Options: Suitable for both retail and wholesale procurement models.
Faster Lead Times: Export-ready logistics reduce delays in urgent oncology supply chains.

WHO reports and global pharmaceutical market data continue to recognize India as a major leader in oncology generic exports. This makes India generic TKI therapy a trusted option for both clinical and commercial buyers in 2026.

Member Manufacturers Directory

Company	Strengths Available	Monthly Capacity	MOQ	Certification	Action
Cipla	100mg / 400mg	1M+ boxes	100 boxes	WHO-GMP, USFDA	Request Quote
Natco Pharma	100mg / 400mg / 50mg / 70mg	900K+ boxes	100 boxes	WHO-GMP, EU GMP	Request Quote
Hetero	Multiple strengths	950K+ boxes	100 boxes	WHO-GMP, USFDA	Request Quote
Sun Pharma	100mg / 400mg	1.2M+ boxes	100 boxes	WHO-GMP, USFDA	Request Quote
Dr. Reddy’s	Full oncology range	850K+ boxes	100 boxes	WHO-GMP, USFDA	Request Quote

Dasatinib the Firstline Therapy — Dasatinib 50mg (USD50-70/box)

Price & Supply Information (2026 Q2 Latest Quotation)

Wholesale Price Range:

Imatinib: USD 35–60/120 tablets per box
Dasatinib: USD 53–56/60 tablets per box

Supply Status: Stable export availability across major Indian manufacturers.

Lead Time: Standard dispatch 7–15 working days depending on destination and documentation.

Download Latest Quotation

Clinical Data & FAQ

Key Clinical Study Summary

The DASISION trial showed Dasatinib achieved faster complete cytogenetic response and major molecular response compared to Imatinib in newly diagnosed chronic phase CML. However, overall long-term survival remained favorable in both groups, making affordability and tolerability major deciding factors for therapy selection.

FAQ

1. Is Dasatinib better than Imatinib for CML?
Dasatinib often produces faster and deeper molecular responses, especially in newly diagnosed patients. However, Imatinib remains highly effective, better tolerated for many patients, and significantly more affordable. The best option depends on physician guidance and patient-specific clinical needs.

2. Why is Imatinib still widely used if Dasatinib is newer?
Imatinib has strong long-term survival data, a well-understood safety profile, and much lower cost through generic availability. Many patients achieve excellent disease control with Imatinib, making it a preferred first-line option in many settings.

3. What are the major side effects of Dasatinib?
Common concerns include pleural effusion, thrombocytopenia, bleeding risk, pulmonary complications, and immune suppression. Regular blood counts and chest symptom monitoring are important during therapy.

4. Can patients switch from Imatinib to Dasatinib?
Yes. Switching may occur due to resistance, intolerance, mutation profile, or inadequate molecular response. This decision should always be made by the treating hematologist.

5. Are India generic versions safe?
Yes. When sourced from WHO-GMP and USFDA-compliant manufacturers, generic versions are widely accepted and used globally. Verified supply channels are important for authenticity and documentation.

6. Which drug is more expensive?
Dasatinib is generally significantly more expensive than Imatinib, especially branded versions. India generics reduce this difference substantially and improve access for long-term therapy.

7. Is Imatinib used outside leukemia treatment?
Yes. Imatinib is also used for GIST, dermatofibrosarcoma protuberans, and several rare hematologic disorders because of its activity against KIT and PDGF pathways.

8. Where can international buyers source reliable supply?
9S Pharmacy Service supports verified sourcing from leading Indian manufacturers with export documentation, quotations, regulatory compliance support, and stable supply planning.

Footer CTA & Trust Signals

Need verified Imatinib or Dasatinib supply support?

Contact 9S Pharmacy Service Now

Trust Badges

WHO-GMP Certified Facilities
USFDA Approved Manufacturers
EDQM Compliance Support
Global Export Documentation
Verified Oncology Supplier Network

Contact: contact@984online.com